Complement biomarker assays play a crucial role in drug development due to the essential role of the complement system in human disorders, providing valuable information about the course and severity of diseases. They are essential tools for diagnosis, disease monitoring, and development of complement-targeting therapies.
This article explores the importance of assessing complement activation and the benefits of using specific and accurate complement biomarker assays in disease diagnosis and treatment.
Incorporating complement biomarker assays into the drug development process provides insights into the cause of complement dysregulation and treatment response.